Timing Better For Sprout’s Latest Shot At First Female Sex Desire Drug
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sprout’s flibanserin resubmission should have an easier time at FDA, as experts backed key aspects of trial design used in flibanserin studies and patients sought treatment options at last year’s workshop on female sexual dysfunction.
You may also be interested in...
A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors
Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.
Sprout’s Female Desire Drug: Size Of Safety Studies Doesn’t Matter To FDA
Flibanserin development can move forward after dispute resolution, but women’s health advocates criticize the delay, charging that FDA has a double standard for female sexual dysfunction drugs.
Resurrected Flibanserin Filing Tests FDA Position On Female Sexual Desire Disorders
With a decision by FDA on a new filing for flibanserin possible by the fall, Sprout hopes to gain the first U.S. approval for treating women with low sexual desire. Meanwhile, Palatin forges on to Phase III with its female sexual desire disorder drug bremelanotide after discussing endpoints with FDA.